GSK Completes $1.15B Acquisition of IDRx to Strengthen Precision Oncology Pipeline

London, UK and Boston, MA, February 24, 2025 (GSK) -- GSK plc (LSE/NYSE: GSK) has completed its acquisition of IDRx, Inc., a Boston-based clinical-stage biopharmaceutical company focused on developing precision therapies for gastrointestinal stromal tumors (GIST). The acquisition includes IDRX-42, an investigational tyrosine kinase inhibitor (TKI) designed to target both primary and secondary KIT mutations, addressing a critical unmet need in GIST treatment. With a total cash consideration of up to $1.15 billion, including a $1 billion upfront payment, GSK plans to advance IDRX-42 for second-line GIST treatment and accelerate its development in earlier stages.

Read full article here.